EcoDrugPlus

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSBSLG00000015955
Gene Symbol: HCN4
3 Cross references
210 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSBSLG00000020190
Gene Symbol: HCN4
3 Cross references
219 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSBSLG00000024683
Gene Symbol: HCRTR2
3 Cross references
201 Possible Orthologues:

Ileal Sodium/bile Acid Cotransporter-Like

Ensembl ID : ENSBSLG00000015115
Gene Symbol: LOC114847560
3 Cross references
211 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1-Like

Ensembl ID : ENSBSLG00000008045
Gene Symbol: LOC114842651
3 Cross references
195 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSBSLG00000012342
Gene Symbol: IKBKB
3 Cross references
198 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSBSLG00000000809
Gene Symbol: IMPDH2
3 Cross references
202 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1a-Like

Ensembl ID : ENSBSLG00000007873
Gene Symbol: LOC114857394
2 Cross references
259 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1b

Ensembl ID : ENSBSLG00000009792
Gene Symbol: LOC114862121
3 Cross references
258 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSBSLG00000000668
Gene Symbol: INPP5D
3 Cross references
216 Possible Orthologues:

Insulin Like Growth Factor 1 Receptor

Ensembl ID : ENSBSLG00000017604
Gene Symbol: IGF1R
3 Cross references
206 Possible Orthologues:

Insulin Receptor-Like

Ensembl ID : ENSBSLG00000008798
Gene Symbol: LOC114854523
3 Cross references
201 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).